395 related articles for article (PubMed ID: 30181579)
1. The oncoprotein HBXIP promotes human breast cancer growth through down-regulating p53 via miR-18b/MDM2 and pAKT/MDM2 pathways.
Li H; Wang Z; Jiang M; Fang RP; Shi H; Shen Y; Cai XL; Liu Q; Ye K; Fan SJ; Zhang WY; Ye LH
Acta Pharmacol Sin; 2018 Nov; 39(11):1787-1796. PubMed ID: 30181579
[TBL] [Abstract][Full Text] [Related]
2. The oncoprotein HBXIP modulates the feedback loop of MDM2/p53 to enhance the growth of breast cancer.
Li H; Liu Q; Wang Z; Fang R; Shen Y; Cai X; Gao Y; Li Y; Zhang X; Ye L
J Biol Chem; 2015 Sep; 290(37):22649-61. PubMed ID: 26229107
[TBL] [Abstract][Full Text] [Related]
3. The role of miR-18b in MDM2-p53 pathway signaling and melanoma progression.
Dar AA; Majid S; Rittsteuer C; de Semir D; Bezrookove V; Tong S; Nosrati M; Sagebiel R; Miller JR; Kashani-Sabet M
J Natl Cancer Inst; 2013 Mar; 105(6):433-42. PubMed ID: 23365201
[TBL] [Abstract][Full Text] [Related]
4. The oncoprotein HBXIP suppresses gluconeogenesis through modulating PCK1 to enhance the growth of hepatoma cells.
Shi H; Fang R; Li Y; Li L; Zhang W; Wang H; Chen F; Zhang S; Zhang X; Ye L
Cancer Lett; 2016 Nov; 382(2):147-156. PubMed ID: 27609066
[TBL] [Abstract][Full Text] [Related]
5. The oncoprotein HBXIP promotes glucose metabolism reprogramming via downregulating SCO2 and PDHA1 in breast cancer.
Liu F; Zhang W; You X; Liu Y; Li Y; Wang Z; Wang Y; Zhang X; Ye L
Oncotarget; 2015 Sep; 6(29):27199-213. PubMed ID: 26309161
[TBL] [Abstract][Full Text] [Related]
6. The oncoprotein HBXIP uses two pathways to up-regulate S100A4 in promotion of growth and migration of breast cancer cells.
Liu S; Li L; Zhang Y; Zhang Y; Zhao Y; You X; Lin Z; Zhang X; Ye L
J Biol Chem; 2012 Aug; 287(36):30228-39. PubMed ID: 22740693
[TBL] [Abstract][Full Text] [Related]
7. The oncoprotein HBXIP upregulates Lin28B via activating TF II D to promote proliferation of breast cancer cells.
Liu Q; Bai X; Li H; Zhang Y; Zhao Y; Zhang X; Ye L
Int J Cancer; 2013 Sep; 133(6):1310-22. PubMed ID: 23494474
[TBL] [Abstract][Full Text] [Related]
8. microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis.
Zhang C; Liu J; Tan C; Yue X; Zhao Y; Peng J; Wang X; Laddha SV; Chan CS; Zheng S; Hu W; Feng Z
Oncotarget; 2016 Feb; 7(8):8783-96. PubMed ID: 26840028
[TBL] [Abstract][Full Text] [Related]
9. The oncoprotein HBXIP upregulates PDGFB via activating transcription factor Sp1 to promote the proliferation of breast cancer cells.
Zhang Y; Zhao Y; Li L; Shen Y; Cai X; Zhang X; Ye L
Biochem Biophys Res Commun; 2013 May; 434(2):305-10. PubMed ID: 23537647
[TBL] [Abstract][Full Text] [Related]
10. Relationship and prognostic significance of phospho-(serine 166)-murine double minute 2 and Akt activation in node-negative breast cancer with regard to p53 expression.
Schmitz KJ; Grabellus F; Callies R; Wohlschlaeger J; Otterbach F; Kimmig R; Levkau B; Schmid KW; Baba HA
Virchows Arch; 2006 Jan; 448(1):16-23. PubMed ID: 16208531
[TBL] [Abstract][Full Text] [Related]
11. miR-339-5p regulates the p53 tumor-suppressor pathway by targeting MDM2.
Jansson MD; Damas ND; Lees M; Jacobsen A; Lund AH
Oncogene; 2015 Apr; 34(15):1908-18. PubMed ID: 24882579
[TBL] [Abstract][Full Text] [Related]
12. The oncoprotein HBXIP enhances angiogenesis and growth of breast cancer through modulating FGF8 and VEGF.
Liu F; You X; Wang Y; Liu Q; Liu Y; Zhang S; Chen L; Zhang X; Ye L
Carcinogenesis; 2014 May; 35(5):1144-53. PubMed ID: 24464787
[TBL] [Abstract][Full Text] [Related]
13. The oncoprotein HBXIP activates transcriptional coregulatory protein LMO4 via Sp1 to promote proliferation of breast cancer cells.
Yue L; Li L; Liu F; Hu N; Zhang W; Bai X; Li Y; Zhang Y; Fu L; Zhang X; Ye L
Carcinogenesis; 2013 Apr; 34(4):927-35. PubMed ID: 23291272
[TBL] [Abstract][Full Text] [Related]
14. Oncoprotein HBXIP induces PKM2 via transcription factor E2F1 to promote cell proliferation in ER-positive breast cancer.
Liu BW; Wang TJ; Li LL; Zhang L; Liu YX; Feng JY; Wu Y; Xu FF; Zhang QS; Bao MZ; Zhang WY; Ye LH
Acta Pharmacol Sin; 2019 Apr; 40(4):530-538. PubMed ID: 29925919
[TBL] [Abstract][Full Text] [Related]
15. Oncoprotein HBXIP Modulates Abnormal Lipid Metabolism and Growth of Breast Cancer Cells by Activating the LXRs/SREBP-1c/FAS Signaling Cascade.
Zhao Y; Li H; Zhang Y; Li L; Fang R; Li Y; Liu Q; Zhang W; Qiu L; Liu F; Zhang X; Ye L
Cancer Res; 2016 Aug; 76(16):4696-707. PubMed ID: 26980761
[TBL] [Abstract][Full Text] [Related]
16. The LXR-623-induced long non-coding RNA LINC01125 suppresses the proliferation of breast cancer cells via PTEN/AKT/p53 signaling pathway.
Wan W; Hou Y; Wang K; Cheng Y; Pu X; Ye X
Cell Death Dis; 2019 Mar; 10(3):248. PubMed ID: 30867411
[TBL] [Abstract][Full Text] [Related]
17. The oncoprotein HBXIP up-regulates SCG3 through modulating E2F1 and miR-509-3p in hepatoma cells.
Wang Y; Cui M; Cai X; Sun B; Liu F; Zhang X; Ye L
Cancer Lett; 2014 Oct; 352(2):169-78. PubMed ID: 24882622
[TBL] [Abstract][Full Text] [Related]
18. miR-520b regulates migration of breast cancer cells by targeting hepatitis B X-interacting protein and interleukin-8.
Hu N; Zhang J; Cui W; Kong G; Zhang S; Yue L; Bai X; Zhang Z; Zhang W; Zhang X; Ye L
J Biol Chem; 2011 Apr; 286(15):13714-22. PubMed ID: 21343296
[TBL] [Abstract][Full Text] [Related]
19. HBXIP regulates etoposide-induced cell cycle checkpoints and apoptosis in MCF-7 human breast carcinoma cells.
Fei HR; Li ZJ; Ying-Zhang ; Yue-Liu ; Wang FZ
Gene; 2018 Mar; 647():39-47. PubMed ID: 29309885
[TBL] [Abstract][Full Text] [Related]
20. The oncoprotein HBXIP competitively binds KEAP1 to activate NRF2 and enhance breast cancer cell growth and metastasis.
Zhou XL; Zhu CY; Wu ZG; Guo X; Zou W
Oncogene; 2019 May; 38(21):4028-4046. PubMed ID: 30692632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]